Business · Companies · 3 hrs ago
Icotec’s spinal implants drive rapid growth as an IPO emerges as a possibility
Icotec is a family-owned medical technology company based in Altstätten, in Switzerland’s St. Gallen region.
It makes implants to replace parts of the spine damaged by cancer, using carbon-reinforced plastic rather than the titanium common in many implants.
The company says its material can help doctors get clearer images when they check for cancer after surgery.
Icotec’s sales rose from $8 million in 2019 to $50 million in 2025, and it has budgeted for $70 million in 2026.
More than 80 percent of its current sales come from the United States, where the company says demand and payment for innovative cancer care are high.
Its growth comes as more doctors consider its products, while potential buyers have also approached the company.
An initial public offering could be a major next step, but the owner family says it wants the company to remain independent.
Icotec, a Swiss medical technology company, has grown its revenue from $8 million in 2019 to $50 million in 2025.
The Altstätten-based company makes carbon-reinforced plastic implants for the spines of cancer patients.
More than 80 percent of its current revenue comes from the United States.
Management has budgeted revenue of $70 million for 2026 and aims to approach $100 million in 2027.
Potential buyers have approached the company, but the owner family insists on its independence.
- Who
- Icotec, a family-owned medical technology company based in Altstätten, Switzerland.
- What
- The company makes spinal implants for cancer patients and has grown rapidly; a stock market listing is a possible next step.
- When
- Revenue rose from 2019 to 2025. Management has budgeted $70 million for 2026 and aims to approach $100 million in 2027.
- Where
- Icotec is based in Altstätten, in the Swiss canton of St. Gallen. More than 80 percent of current revenue comes from the United States.
- Why
- The company focused on spinal implants for cancer patients after identifying potential in this medical technology niche. It says carbon-reinforced plastic offers advantages over metal implants.
This story does not have two clearly opposing sides.
Metastases are no longer a death sentence.
Metal implants are stiff as a board. Our carbon products, by contrast, have a slight elasticity.
That benefits the spine. Bones want to move slightly.
Icotec began focusing on screws, plates and other spinal implants for cancer patients.
The family-owned company’s revenue rose from $8 million to $50 million.
Christoph Eigenmann joined Icotec after working for Johnson & Johnson for 20 years.
Management budgeted revenue of $70 million for the year.
Management aims to bring revenue close to $100 million for the first time.
- Headquarters
- Altstätten, canton of St. Gallen, Switzerland
- Revenue in 2019
- $8 million
- Revenue in 2025
- $50 million
- Share of current revenue from the United States
- More than 80 percent
- Budgeted 2026 revenue
- $70 million
- 2027 revenue target
- Close to $100 million
Sources
Related news
Investor sees value in overlooked US stocks and regional banks
BNP Paribas targets €100 billion in ETF inflows by 2030
Nicolai Nussbaumer joins Alpen Partners after 22 years at Rahn+Bodmer
ZKB faces claims of abrupt staff changes in its direct banking unit
Ascend plans SIX listing through merger with EvoNext
Adel Abdel-Latif seeks $7.9 million from Dubai investment firm
High oil prices put pressure on several Swiss-listed companies
Lastminute appoints Ludovic Boisseau as finance chief from November 16
Centiel cuts 2026 forecast as US deliveries move to 2027
Swiss SMI rises for the week after a volatile trading period
S&P gives Zurich a negative financial outlook while keeping its top rating
